Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants-Reference-Cited by-同舟云学术

Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants

Published:2017-02 Issue:2 Volume:49 Page:157-162
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Macaluso Fabio Salvatore^ORCID,Maida Marcello,Renna Sara,Orlando Emanuele,Affronti Marco,Sapienza Chiara,Dimarco Mariangela,Orlando Rosalba,Rizzuto Giulia,Cottone Mario,Orlando Ambrogio

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management;Dignass;Journal of Crohn’s and Colitis,2010

2. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management;Dignass;Journal of Crohn’s and Colitis,2012

3. Frequency of glucocorticoid resistance and dependency in Crohn’s disease;Munkholm;Gut,1994

4. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease;Renna;World Journal of Gastroenterology,2014

5. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the ameliorative potential of Bacopa monnieri in acetic acid induced ulcerative colitis in mice;Natural Product Research;2023-07-10

2. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry;Digestive and Liver Disease;2021-11

3. Secondary causes of inflammatory bowel diseases;World Journal of Gastroenterology;2020-07-28

4. The role of immunosuppressive agents in the management of severe and refractory immune‐related adverse events;Asia-Pacific Journal of Clinical Oncology;2020-03-24

5. The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study;Inflammatory Bowel Diseases;2018-01-18